

Montana Healthcare Programs Prior Authorization Request Form for Use of Wakix (pitolisant)

Member Name:	DOB:	Date:
Member ID:	Prescriber Phone:	Prescriber Fax:
Prescriber Name/Specialty if applicable:	Dose Requested:	

Please complete below information for applicable situation, Initiation or Continuation of therapy:

☐ INITIATION OF THERAPY

- Member is ≥ 18 years of age: ☐ Yes ☐ No (required)
- Member must have a diagnosis of narcolepsy with excessive daytime sleepiness (EDS) that impacts activities of daily living: ☐ Yes ☐ No
- Member has had an inadequate response, intolerance to, or contraindication to ALL of the following:
 - ☐ CNS stimulant (i.e., methylphenidate, dextroamphetamine, etc). Drug _____ Date: _____
 - ☐ Modafinil OR ☐ Armodafinil Date: _____
 - ☐ Sunosi Date: _____

☐ Provider acknowledges the member has been assessed for the following clinically significant drug interactions*:

Category	Clinical Implication	Prevention/Management	Examples
Strong CYP2D6 Inhibitors	↑ exposure to pitolisant by 2.2-fold	Reduce Wakix dose by half	Paroxetine, fluoxetine, bupropion
Strong CYP3A4 Inducers	↓ exposure of pitolisant by 50%	Assess for loss of efficacy and consult package insert for Wakix dosing adjustments	Rifampin, carbamazepine, phenytoin
Histamine-1 (H1) Receptor Antagonists	↑ brain histamine levels	Avoid centrally acting H1 receptor antagonists	Pheniramine, diphenhydramine, promethazine, imipramine, clomipramine, mirtazapine
QT Interval Prolonging Medications	Additive QT prolongation/↑ arrhythmia risk	Avoid with drugs known to prolong QT interval	Quinidine, procainamide, disopyramide, amiodarone, sotalol, ziprasidone, chlorpromazine, thioridazine, moxifloxacin
Sensitive CYP3A4 Substrates	↓ effectiveness of substrate	Use alternative contraceptive during tx and 21 days after DC	Midazolam, hormonal contraceptives, cyclosporine

*Consult package insert for complete drug interaction information

LIMITATIONS: Maximum of 35.6mg per day (dose optimization required). **Initial authorization will be issued for 6 months.**

☐ CONTINUATION OF THERAPY

Provider attests member has achieved a clinically meaningful response to treatment ☐ Yes ☐ No

Reauthorization will be issued for 12 months.

**Please complete form, including required attachments and fax to:
Drug Prior Authorization Unit at 1-800-294-1350**